Back to Directory Susan Ford Email susan.l.ford@gsk.com Phone 919-483-0392 Institution ViiV Healthcare Address ViiV 5 Moore Drive Research Triangle Park, NC 27709 Request an Update Affiliated Studies IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending IMPAACT 2017: MOCHA DAIDS Number 30070 Research Area Therapeutics Study Status Closed to Accrual
IMPAACT 2040: Phase I/II Study of the Pharmacokinetics and Safety of Long-Acting Injectable Cabotegravir and Rilpivirine in Pregnant and Postpartum Adults with HIV-1 DAIDS Number 38953 Research Area Therapeutics Study Status Pending